An Introduction to Macular Degeneration
The treatment landscape for macular degeneration is evolving with many new potential therapies under investigation. The standard of care in wet age-related macular degeneration (AMD) was revolutionised in 2005 with the introduction of anti-VEGF therapies, and current research into port delivery systems and drug combinations aim to provide longer-lasting treatments. Dry AMD is a challenging condition with no current treatment option, but research into stem cell therapies and drugs that slow the progression of geographic atrophy show much promise.
Browse the content below, to see leading experts discuss the latest data in video interviews and short articles from our conference hub. You can also view the selection of peer-reviewed articles from our journals. If you’re looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.
Our supporting partners do not constitute an endorsement of the content on this page.
Macular Degeneration Content
Jordana Fein, ARVO 2023: Phase II CANDELA study post hoc analysis: intravitreal aflibercept injection 8 mg versus 2 mg
The CANDELA trial (NCT04126317) was a phase II, randomized, single-masked, open-label, clinical trial that assessed the safety and efficacy of aflibercept 8 mg versus the standard dose of 2 mg in patients with neovascular age-related macular degeneration (nAMD). It was a pleasure to speak with Dr Jordana Fein (Retina Group of Washington Fairfax, VA, USA) […]
Jordana Fein, ARVO 2023: Current therapeutic options for neovascular age-related macular degeneration
Neovascular age-related macular degeneration (nAMD) is an advanced form of macular degeneration that historically has accounted for the majority of vision loss related to AMD. Current treatment consists of injecting inhibitors of vascular endothelial growth factor (VEGF) into the vitreous cavity to interfere with proliferation of choroidal neovascularization and to reduce vascular permeability. It was […]
High-dose Aflibercept with Increased Dosing Intervals as a New Standard of Care for DMO and nAMD
touchREVIEWS in Ophthalmology. 2023;17(1):8–9 DOI: https://doi.org/10.17925/USOR.2023.17.1.8
With the introduction of monoclonal antibody inhibitors for all isoforms of vascular endothelial growth factor (VEGF)-A, which were first presented in September 2005 with off-label use of bevacizumab, significant anatomical and visual improvements for neovascular age-related macular degeneration (nAMD) became a reality. Following the landmark ANCHOR and MARINA trials, which showed that monthly ranibizumab injections resulted in 7.2–11.0 Early Treatment Diabetic Retinopathy Study (ETDRS) letters gained after 1 year of treatment, anti-VEGF agents became the standard of care for nAMD.1,2 The […]
Ranibizumab Biosimilars for Neovascular Age-related Macular Degeneration, Macular Oedema with Retinal Vein Occlusion and Myopic Choroidal Neovascularization
touchREVIEWS in Ophthalmology. 2022;16(2):80–4 DOI: https://doi.org/10.17925/USOR.2022.16.2.80
The subspecialty of the retina has been transformed by anti-vascular endothelial growth factor (anti-VEGF) medications over the last two decades.1 These include bevacizumab (Avastin®, Genetech, San Francisco, CA, USA), ranibizumab (Lucentis®, Genentech, San Francisco, CA, USA), aflibercept (Eylea®, Regeneron Pharmaceuticals, Tarrytown, NY, USA), brolicizumab (Beovu®, Novartis, Basel, Switzerland) and faricimab (Vabsymo™, Genentech, San Francisco, CA, USA), […]
Dilsher Dhoot, AAO 2022: Sustained-release axitinib hydrogel implant in wet AMD, phase 1 results
A sustained-release axitinib hydrogel implant poses advantages for the treatment of wet age-related macular degeneration (wet AMD). In this touchOPHTHALMOLOGY interview, we speak with Dr Dilsher Dhoot (California Retina Consultants, Santa Barbara, CA, USA) to discuss the phase 1 study of the axitinib hydrogel implant, its findings and the next steps for its development. The […]
Rahul Khurana, AAO 2022: Loss to follow-up in patients with nAMD treated with anti-VEGF therapy in the US
Dr Rahul Khurana (Northern California Retina Vitreous Associates, Mountain View, CA, USA) took part in a retrospective cohort study investigating the incidence of loss to follow-up after anti–vascular endothelial growth factor (VEGF) injections among patients with neovascular age-related macular degeneration. In this interview, he discusses with touchOPHTHALMOLOGY the design and findings of this study as […]
Francesco Bandello, EURETINA 2022: The Relationship Between OCTA and FA/ICGA in AMD Part 1
In this touchOPHTHALMOLOGY interview, Prof. Francesco Bandello (Department of Ophthalmology University Vita-Salute Scientific Institute San Raffaele, Milan, Italy) talks us through the advantages of optical coherence tomography angiography (OCTA) over conventional dye angiography in age-related macular degeneration (AMD) and a study investigating the relationship between OCTA and fluorescein angiography/indocyanine green angiography in AMD. ‘Morphological and […]
Francesco Bandello, EURETINA 2022: The Relationship Between OCTA and FA/ICGA in AMD Part 2
In this touchOPHTHALMOLOGY interview, Prof. Francesco Bandello (Department of Ophthalmology University Vita-Salute Scientific Institute San Raffaele, Milan, Italy) discussed the findings of a study investigating the relationship between optical coherence tomography angiography and fluorescein angiography/indocyanine green angiography in AMD and their implications. ‘Morphological and Functional Relationship Between OCTA and FA/ICGA in AMD’ was presented at […]
Usha Chakravarthy, EURETINA 2022: Persistent fluid in neovascular age-related macular degeneration
The Archway study (NCT03677934) was a phase 3, randomized, active treatment–controlled trial for the treatment of nAMD, conducted at 77 study locations in the United States. We caught up with Prof. Usha Chakravarthy (Queen’s University of Belfast, Belfast, Northern Ireland) to discuss the causes of persistent fluid in neovascular age-related macular degeneration and the impact […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!